---
title: "Cadrenal Therapeutics Reports Clinical Data From Phase 2 Study Of CAD-1005"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292499077.md"
description: "Cadrenal Therapeutics (CVKD) presented late-breaking Phase 2 clinical data for CAD-1005, showing a >25% reduction in thrombotic events in Heparin-Induced Thrombocytopenia. CEO Quang Pham stated the company is well-positioned to advance partnering opportunities following recent financing. CAD-1005 holds FDA Orphan Drug and Fast Track designations. Meanwhile, Cadrenal shares fell 7.27% to $2.68."
datetime: "2026-07-13T13:52:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292499077.md)
  - [en](https://longbridge.com/en/news/292499077.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292499077.md)
---

# Cadrenal Therapeutics Reports Clinical Data From Phase 2 Study Of CAD-1005

Add  as your preferred news source on Google

 Add Now

Cadrenal Therapeutics (CVKD) presented late-breaking clinical data from the Phase 2 study of the 12-lipoxygenase inhibitor CAD-1005. The Phase 2 Data demonstrated greater than 25% reduction in Thrombotic events in Heparin-Induced Thrombocytopenia for CAD-1005.

Quang Pham, CEO of Cadrenal Therapeutics said: "With our recent financing, we are well-positioned to advance partnering opportunities for CAD-1005 and tecarfarin."

CAD-1005 has received Orphan Drug and Fast Track designations from the FDA and Orphan Drug status from the European Medicines Agency.

Cadrenal Therapeutics shares are currently down 7.27 percent to $2.68.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [CVKD.US](https://longbridge.com/en/quote/CVKD.US.md)

## Related News & Research

- [Cadrenal Therapeutics highlights Phase 2 data for CAD-1005 in heparin-induced thrombocytopenia, eyes CSA-AKI market](https://longbridge.com/en/news/294693587.md)
- [Cadrenal says Phase 2 trial of CAD-1005 cuts thrombotic events by more than 25% in HIT](https://longbridge.com/en/news/292495231.md)
- [Bank Stock Merger Mania Might Not Happen. This ETF Explains Why.](https://longbridge.com/en/news/296001990.md)
- [Oil edges lower amid mixed signals](https://longbridge.com/en/news/295864356.md)
- [These bonds offer a rare buying opportunity](https://longbridge.com/en/news/295523065.md)